These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 26964888)

  • 1. Fast and Efficient Fragment-Based Lead Generation by Fully Automated Processing and Analysis of Ligand-Observed NMR Binding Data.
    Peng C; Frommlet A; Perez M; Cobas C; Blechschmidt A; Dominguez S; Lingel A
    J Med Chem; 2016 Apr; 59(7):3303-10. PubMed ID: 26964888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and generation of highly diverse fluorinated fragment libraries and their efficient screening with improved (19) F NMR methodology.
    Vulpetti A; Dalvit C
    ChemMedChem; 2013 Dec; 8(12):2057-69. PubMed ID: 24127294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hit-to-Lead: Hit Validation and Assessment.
    Hevener KE; Pesavento R; Ren J; Lee H; Ratia K; Johnson ME
    Methods Enzymol; 2018; 610():265-309. PubMed ID: 30390802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hot-Spotting with Thermal Scanning: A Ligand- and Structure-Independent Assessment of Target Ligandability.
    Chilton M; Clennell B; Edfeldt F; Geschwindner S
    J Med Chem; 2017 Jun; 60(12):4923-4931. PubMed ID: 28537726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical aspects of NMR-based fragment screening.
    Lepre CA
    Methods Enzymol; 2011; 493():219-39. PubMed ID: 21371593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of Biophysics in High-Throughput Screening Hit Validation.
    Genick CC; Barlier D; Monna D; Brunner R; Bé C; Scheufler C; Ottl J
    J Biomol Screen; 2014 Jun; 19(5):707-14. PubMed ID: 24695619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery.
    Wu B; Zhang Z; Noberini R; Barile E; Giulianotti M; Pinilla C; Houghten RA; Pasquale EB; Pellecchia M
    Chem Biol; 2013 Jan; 20(1):19-33. PubMed ID: 23352136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-Based Ligand Designing.
    Katiyar SP; Malik V; Kumari A; Singh K; Sundar D
    Methods Mol Biol; 2018; 1762():123-144. PubMed ID: 29594771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR screening in fragment-based drug design: a practical guide.
    Kim HY; Wyss DF
    Methods Mol Biol; 2015; 1263():197-208. PubMed ID: 25618347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of Solution NMR in Drug Discovery.
    Shi L; Zhang N
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based ligand discovery.
    Fischer M; Hubbard RE
    Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMR spectroscopy: the swiss army knife of drug discovery.
    Horst R; Farley KA; Kormos BL; Withka JM
    J Biomol NMR; 2020 Nov; 74(10-11):509-519. PubMed ID: 32617727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based lead discovery and design.
    Joseph-McCarthy D; Campbell AJ; Kern G; Moustakas D
    J Chem Inf Model; 2014 Mar; 54(3):693-704. PubMed ID: 24490951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMR screening and hit validation in fragment based drug discovery.
    Campos-Olivas R
    Curr Top Med Chem; 2011; 11(1):43-67. PubMed ID: 20809889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R; Wang P; Wu J; Ruan K
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand specificity, privileged substructures and protein druggability from fragment-based screening.
    Barelier S; Krimm I
    Curr Opin Chem Biol; 2011 Aug; 15(4):469-74. PubMed ID: 21411360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.